Cipla | CIPLA - Cash And Equivalent


Cipla reported INR7.96B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Dr.Reddys Laboratories INR 18.66B 8.75B Dec/2025
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
TherapeuticsMD 523K 89K Jun/2024
UPL INR 41.52B 53.85B Sep/2025